WEDNESDAY, May 30, 2018 — BRCA1/BRCA2 germline mutation carriers with pancreatic ductal adenocarcinoma (PDAC) have worse survival after resection, according to a study published in the April issue of the Journal of the American College of…

Related Links:

Platinum-based therapy may improve survival in pancreatic ductal adenocarcinoma carrying deleterious germline mutations.JCO Precision Oncology

Source: Medscape Today HeadlinesCategory: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

ConclusionsTumor size was a significant predictive factor for RFS and OS in PDAC patients. Although entropy with medium texture analysis was significantly associated with OS, there were also limitations in the texture analysis; thus, further study is necessary.

Publication date: Available online 28 June 2018Source: Advances in Biological RegulationAuthor(s): Stephen L. Abrams, Kvin Lertpiriyapong, Li V. Yang, Alberto M. Martelli, Lucio Cocco, Stefano Ratti, Marco Falasca, Ramiro M. Murata, Pedro L. Rosalen, Paolo Lombardi, Massimo Libra, Saverio Candido, Giuseppe Montalto, Melchiorre Cervello, Linda S. Steelman, James A. McCubreyAbstractPancreatic ductal adenocarcinoma (PDAC) is an aggressive, highly metastatic malignancy and accounts for 85% of pancreatic cancers. PDAC patients have poor prognosis with a five-year survival of only 5–10%. Mutations at the TP53 gene are read…

Publication date: May 2018Source: Advances in Biological Regulation, Volume 68Author(s): Saverio Candido, Stephen L. Abrams, Linda Steelman, Kvin Lertpiriyapong, Alberto M. Martelli, Lucio Cocco, Stefano Ratti, Matilde Y. Follo, Ramiro M. Murata, Pedro L. Rosalen, Paolo Lombardi, Giuseppe Montalto, Melchiorre Cervello, Agnieszka Gizak, Dariusz Rakus, Pann-Gill Suh, Massimo Libra, James A. McCubreyAbstractPancreatic ductal adenocarcinoma (PDAC) is an aggressive, highly metastatic malignancy and accounts for 85% of pancreatic cancers. PDAC patients have poor prognosis with a five-year survival of only 5–10% after diagn…

Publication date: May 2018Source: Advances in Biological Regulation, Volume 68Author(s): Aleksandra Adamska, Omar Elaskalani, Aikaterini Emmanouilidi, Minkyoung Kim, Norbaini Binti Abdol Razak, Pat Metharom, Marco FalascaAbstractPancreatic Ductal Adenocarcinoma (PDAC) is one of the most chemoresistant cancers, and current therapies targeting cancer-associated molecular pathways have not given satisfactory results, owing in part to rapid upregulation of alternative compensatory pathways. Most of the available treatments are palliative, focussing on improving the quality of life. At present, available options are surgery, em…

ConclusionsThe CRP/Alb ratio at POD14 is a useful predictive marker of surgical invasion, biological reaction, and prognosis in PDAC patients.

ConclusionCombination of systemic chemotherapy and oligometastasectomy with adjunctive local IRE therapy is a feasible treatment strategy in highly select patients with oligometastatic PDAC that demonstrate favorable tumor biology with objective response to systemic therapy.

ConclusionsThere have been significant improvements in pancreatic cancer care over the last decade, as evidenced by earlier diagnosis, increased utilization of surgery, and improvement in overall survival for both resected and un-resected patients.

ConclusionsSurgical resection should be considered, if possible, in patients with pancreatobiliary fistulas associated with IPMNs. A better prognosis is expected with prevention of obstructive jaundice or cholangitis.

ConclusionIt is important to be keep in mind that there is a possibility of ITPN after diagnosis of idiopathic acute pancreatitis.





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image